| Literature DB >> 35325594 |
Rodrigo Nalio Ramos1, Yoann Missolo-Koussou1, Yohan Gerber-Ferder1, Christian P Bromley2, Mattia Bugatti3, Nicolas Gonzalo Núñez1, Jimena Tosello Boari1, Wilfrid Richer1, Laurie Menger4, Jordan Denizeau1, Christine Sedlik1, Pamela Caudana1, Fiorella Kotsias1, Leticia L Niborski1, Sophie Viel1, Mylène Bohec5, Sonia Lameiras5, Sylvain Baulande5, Laëtitia Lesage6, André Nicolas6, Didier Meseure6, Anne Vincent-Salomon6, Fabien Reyal7, Charles-Antoine Dutertre8, Florent Ginhoux9, Lene Vimeux10, Emmanuel Donnadieu10, Bénédicte Buttard11, Jérôme Galon11, Santiago Zelenay2, William Vermi12, Pierre Guermonprez13, Eliane Piaggio1, Julie Helft14.
Abstract
Macrophage infiltration is a hallmark of solid cancers, and overall macrophage infiltration correlates with lower patient survival and resistance to therapy. Tumor-associated macrophages, however, are phenotypically and functionally heterogeneous. Specific subsets of tumor-associated macrophage might be endowed with distinct roles on cancer progression and antitumor immunity. Here, we identify a discrete population of FOLR2+ tissue-resident macrophages in healthy mammary gland and breast cancer primary tumors. FOLR2+ macrophages localize in perivascular areas in the tumor stroma, where they interact with CD8+ T cells. FOLR2+ macrophages efficiently prime effector CD8+ T cells ex vivo. The density of FOLR2+ macrophages in tumors positively correlates with better patient survival. This study highlights specific roles for tumor-associated macrophage subsets and paves the way for subset-targeted therapeutic interventions in macrophages-based cancer therapies.Entities:
Keywords: CD8(+) T lymphocytes; FOLR2; TREM2; breast cancer; single-cell RNA sequencing; tissue-resident macrophages
Mesh:
Substances:
Year: 2022 PMID: 35325594 DOI: 10.1016/j.cell.2022.02.021
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582